Alphadyne Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.27M Buy
119,800
+23,100
+24% +$1.35M 0.13% 228
2025
Q4
$5.22M Buy
96,700
+78,600
+434% +$3.78M 0.12% 138
2025
Q3
$816K Buy
+18,100
New +$845K 0.07% 210
2024
Q1
Sell
-13,300
Closed -$682K 27
2023
Q4
$682K Sell
13,300
-4,600
-26% -$241K 0.25% 21
2023
Q3
$1.04M Hold
17,900
0.08% 143
2023
Q2
$1.14M Buy
+17,900
New +$1.2M 0.14% 64

Other funds holding BMY

Alphadyne Asset Management's BMY Position: Q4 2025 in Review

Alphadyne Asset Management sold out of Bristol-Myers Squibb (BMY) in Q4 2025, closing a stake of 3,982 shares — an estimated $192K sold.

Alphadyne Asset Management first reported a position in BMY in Q2 2023 and held it in 4 quarters. The position peaked at $663K in Q4 2023. 2,447 funds tracked by Wall St. Rank hold BMY as of Q4 2025.

  • Alphadyne Asset Management reported no remaining Bristol-Myers Squibb position as of Q4 2025 after selling out during the quarter.
  • Alphadyne Asset Management sold 3,982 Bristol-Myers Squibb shares in Q4 2025, an estimated $192K.
  • Alphadyne Asset Management first reported a position in Bristol-Myers Squibb in Q2 2023 and held it in 4 quarters.
  • Alphadyne Asset Management's Bristol-Myers Squibb position peaked at $663K in Q4 2023.
  • 2,447 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2025.

Based on Alphadyne Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.